146 related articles for article (PubMed ID: 38868744)
21. Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.
Weisbrod AB; Zhang L; Jain M; Barak S; Quezado MM; Kebebew E
Horm Cancer; 2013 Jun; 4(3):165-75. PubMed ID: 23361940
[TBL] [Abstract][Full Text] [Related]
22. Distinct DNA Methylation Signatures in Neuroendocrine Tumors Specific for Primary Site and Inherited Predisposition.
Tirosh A; Killian JK; Petersen D; Zhu YJ; Walker RL; Blau JE; Nilubol N; Patel D; Agarwal SK; Weinstein LS; Meltzer P; Kebebew E
J Clin Endocrinol Metab; 2020 Oct; 105(10):3285-94. PubMed ID: 32706863
[TBL] [Abstract][Full Text] [Related]
23. Uncovering the heterogeneous genetic variations in two insulin-expressing tumors in a patient with MEN1.
Wang Z; Liu L; Luo J; Guo J; Zhai M; Zhang W; Yang Z
Oncol Lett; 2018 May; 15(5):7123-7131. PubMed ID: 29725435
[TBL] [Abstract][Full Text] [Related]
24. MEN1 gene mutations in sporadic neuroendocrine tumors of foregut derivation.
Fujii T; Kawai T; Saito K; Hishima T; Hayashi Y; Imura J; Hironaka M; Hosoya Y; Koike M; Fukayama M
Pathol Int; 1999 Nov; 49(11):968-73. PubMed ID: 10594843
[TBL] [Abstract][Full Text] [Related]
25. Genetic and epigenetic alterations in pancreatic neuroendocrine tumors.
Tirosh A; Kebebew E
J Gastrointest Oncol; 2020 Jun; 11(3):567-577. PubMed ID: 32655936
[TBL] [Abstract][Full Text] [Related]
26. Whole-exome sequencing as a tool for searching for genetic background modifiers in MEN1 patients with neuroendocrine pancreatic tumours, including insulinomas.
Skalniak A; Trofimiuk-Müldner M; Jabrocka-Hybel A; Totoń-Żurańska J; Wołkow P; Hubalewska-Dydejczyk A
Endokrynol Pol; 2023; 74(1):31-46. PubMed ID: 36847722
[TBL] [Abstract][Full Text] [Related]
27. Current and emerging therapies for PNETs in patients with or without MEN1.
Frost M; Lines KE; Thakker RV
Nat Rev Endocrinol; 2018 Apr; 14(4):216-227. PubMed ID: 29449689
[TBL] [Abstract][Full Text] [Related]
28. Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor.
Williamson LM; Steel M; Grewal JK; Thibodeau ML; Zhao EY; Loree JM; Yang KC; Gorski SM; Mungall AJ; Mungall KL; Moore RA; Marra MA; Laskin J; Renouf DJ; Schaeffer DF; Jones SJM
Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160355
[TBL] [Abstract][Full Text] [Related]
29. Pancreatic Neuroendocrine Tumors: an Update.
Paniccia A; Edil BH; Schulick RD
Indian J Surg; 2015 Oct; 77(5):395-402. PubMed ID: 26722203
[TBL] [Abstract][Full Text] [Related]
30. Genomic profiling of multiple tissues in two patients with multiple endocrine neoplasia type 1.
Naruoka A; Ohnami S; Nagashima T; Serizawa M; Hatakeyama K; Ohshima K; Ohnami S; Urakami K; Horiuchi Y; Kiyozumi Y; Matsubayashi H; Abe M; Ohishi T; Kameya T; Sugino T; Onitsuka T; Isaka M; Ohde Y; Sugiura T; Ito T; Uesaka K; Akiyama Y; Kusuhara M; Yamaguchi K
Biomed Res; 2021; 42(2):89-94. PubMed ID: 33840689
[TBL] [Abstract][Full Text] [Related]
31. Distinct Prognostic Factors in Sporadic and Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors.
Kfir SK; Halperin R; Percik R; Uri I; Halpern N; Shlomai G; Laish I; Tirosh A; Tirosh A
Horm Metab Res; 2021 May; 53(5):319-325. PubMed ID: 33878789
[TBL] [Abstract][Full Text] [Related]
32. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
Faggiano A; Modica R; Lo Calzo F; Camera L; Napolitano V; Altieri B; de Cicco F; Bottiglieri F; Sesti F; Badalamenti G; Isidori AM; Colao A
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31586182
[TBL] [Abstract][Full Text] [Related]
33. DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications.
Liu IH; Ford JM; Kunz PL
Cancer Treat Rev; 2016 Mar; 44():1-9. PubMed ID: 26924193
[TBL] [Abstract][Full Text] [Related]
34. Identification of MEN1 mutations in sporadic enteropancreatic neuroendocrine tumors by analysis of paraffin-embedded tissue.
Mailman MD; Muscarella P; Schirmer WJ; Ellison EC; O'Dorisio TM; Prior TW
Clin Chem; 1999 Jan; 45(1):29-34. PubMed ID: 9895334
[TBL] [Abstract][Full Text] [Related]
35. Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor.
Quevedo R; Spreafico A; Bruce J; Danesh A; El Ghamrasni S; Giesler A; Hanna Y; Have C; Li T; Yang SYC; Zhang T; Asa SL; Haibe-Kains B; Krzyzanowska M; Smith AC; Singh S; Siu LL; Pugh TJ
Genome Med; 2020 Apr; 12(1):38. PubMed ID: 32345369
[TBL] [Abstract][Full Text] [Related]
36. Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors.
Tirosh A; Mukherjee S; Lack J; Gara SK; Wang S; Quezado MM; Keutgen XM; Wu X; Cam M; Kumar S; Patel D; Nilubol N; Tyagi MV; Kebebew E
Cancer; 2019 Apr; 125(8):1247-1257. PubMed ID: 30620390
[TBL] [Abstract][Full Text] [Related]
37. MEN4 and
Alrezk R; Hannah-Shmouni F; Stratakis CA
Endocr Relat Cancer; 2017 Oct; 24(10):T195-T208. PubMed ID: 28824003
[TBL] [Abstract][Full Text] [Related]
38. The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours.
Pipinikas CP; Berner AM; Sposito T; Thirlwell C
Endocr Relat Cancer; 2019 Aug; 26(9):R519-R544. PubMed ID: 31252410
[TBL] [Abstract][Full Text] [Related]
39. ONCOGENE PANEL SEQUENCING ANALYSIS IDENTIFIES CANDIDATE ACTIONABLE GENES IN ADVANCED WELL-DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS.
Tirosh A; Killian JK; Zhu YJ; Petersen D; Walling J; Mor-Cohen R; Neychev V; Stevenson H; Keutgen XM; Patel D; Nilubol N; Meltzer P; Kebebew E
Endocr Pract; 2019 Jun; 25(6):580-588. PubMed ID: 30865533
[No Abstract] [Full Text] [Related]
40. Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors.
Modali SD; Parekh VI; Kebebew E; Agarwal SK
Mol Endocrinol; 2015 Feb; 29(2):224-37. PubMed ID: 25565142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
